Medigene AG Namen-Akt. nach Kapitalherabsetzung MDG2
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 87
- Website
- https://www.medigene.com
Comparables
Valuation
|
Metric
|
MDG2
|
HPHA
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.50 | 3.26 | 0.89 |
Price/Sales | 3.58 | 11.31 | 22.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
MDG2
HPHA
NYKD
Financial Strength
|
Metric
|
MDG2
|
HPHA
|
NYKD
|
|---|---|---|---|
Quick Ratio | 2.22 | 4.85 | 9.28 |
Current Ratio | 2.39 | 6.13 | 9.28 |
Interest Coverage | −50.21 | −36.58 | — |
Quick Ratio
MDG2
HPHA
NYKD
Profitability
|
Metric
|
MDG2
|
HPHA
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −46.14% | −16.41% | −17.82% |
Return on Equity (Normalized) | −66.82% | −29.22% | −22.35% |
Return on Invested Capital (Normalized) | −58.40% | −24.71% | −25.52% |
Return on Assets
MDG2
HPHA
NYKD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vtmzhjbjsh | Wvjz | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Znrcvsdf | Nnmrcs | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mjkfmthg | Kyynnd | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Szjzkrzz | Mkrdn | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Pjwgrqhd | Knzb | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Rprlvrxtv | Tdkv | $28.0 Bil | |||
| Moderna Inc
MRNA
| Dmnzzwtl | Dnvyq | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Xyyfjmbh | Bff | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jhnvmbxlt | Pzybrl | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ckvfcdfsm | Fswrzn | $12.6 Bil |
United States